Psoriasis

Evidence-Based Dermatology: Second Edition

Volumn , Issue , 2009, Pages 171-188

  Naldi, Luigi ^a   Chalmers, Robert J G ^b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

European Dermatoepidemiology Network (EDEN) database of psoriasis trials; Guttate psoriasis; Palmoplantar pustular psoriasis; Psoralen ultraviolet A (PUVA) for psoriasis clearance; Psoriasis inflammatory skin disease; PUVA versus psoralen plus UVB; Salicylic acid keratolytic agent in dermatological practice; Systemic retinoid monotherapy; Treatments for acropustulosis (acrodermatitis continua of Hallopeau)

Indexed keywords

EID: 84889356915     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300161.ch21     Document Type: Chapter

References (89)

1. Franssen MJAM, van den Hoogen FHJ, van de Putte LBA. Psoriatic arthropathy. In: van de Kerkhof PCM, editor. Textbook of Psoriasis. Oxford: Blackwell Science, 1999:30-42.
2. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128:39-42.
3. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003;120:627-32.
4. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-8.
5. Giardina E, Sinibaldi C, Novelli G. The psoriasis genetics as a model of complex disease. Curr Drug Targets Inflamm Allergy 2004;3:129-36.
6. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30.
7. Sommer D, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
8. De Korte J, Sprangers MAG, Mombers FMC, et al. Quality of life in patients with psoriasis: a systematic literature review. J Invest Dermatol Symp Proc 2004;9:140-7.
9. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125.
10. Watsky KL, Freije L, Leneveu MC, Wenck HA, Leffell DJ. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 1992;50:383-6.
11. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Dermatovenereol 1996;76:353-6.
12. Fredriksson TLM. A blind controlled comparison between a new cream ("12 + 12"), its vehicle, and salicylic acid in petrolatum on psoriatic plaques. Curr Ther Res 1985;37:805-9.
13. Friedman SJ. Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987;123:1046-52.
14. David M, Lowe NJ. Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989;21:511-4.
15. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146: 351-64.
16. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-sali-cylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998; 20:283-91.
17. Kristensen B, Kristensen O. Topical salicylic acid interferes with UVB therapy for psoriasis. Acta Dermatovenereol 1991;71:37-40.
18. Naldi L, Carrel CF, Parazzini F, et al. Development of anthralin short-contact therapy in psoriasis: survey of published clinical trials. Int J Dermatol 1992;31:126-30.
19. van de Kerkhof PC, Chang A, van der Walle HB, et al. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Acta Derm Venereol 1994; 74:143-6.
20. Dezfoulian B, De la Brassinne M, Rosillon D. A new generation of hydrocolloid dressings in combination with topical corticosteroids in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1997;9:50-3.
21. Volden G, Kragballe K, van de Kerkhof PC, et al. Remission and relapse of chronic plaque psoriasis treated once a week with clo-betasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatol Treat 2001;12:141-4.
22. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57-60.
23. de Jong EM, Mork NJ, Seijger MM, et al. The combination of cal-cipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003;148:318-25.
24. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48:760-7.
25. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.
26. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high-or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002; 6:95-102.
27. Gollnick H, Menter A. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;140(Suppl):18-23.
28. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39:590-6.
29. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22:1225-38.
30. Snellman E, Aromaa A, Jansen CT, et al. Supervised four-week heliotherapy alleviates the long-term course of psoriasis. Acta Derm Venereol 1993;73:388-92.
31. Frentz G, Olsen JH, Avrach WW. Malignant tumours and psoriasis: climatotherapy at the Dead Sea. Br J Dermatol 1999;141:1088-91.
32. Cameron H, Dawe RS, Yule S, et al. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002; 147:973-8.
33. Stern RS, Armstrong RB, Anderson TF, et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis. A randomized study. J Am Acad Dermatol 1986; 15:546-52.
34. Boer J, Hermans J, Schothorst AA, et al. Comparison of phototherapy (UVB) and photochemotherapy (PUVA) for clearing and maintenance therapy of psoriasis. Arch Dermatol 1984;120:52-7.
35. Gordon PM, Diffey BL, Mathews JN, et al. A randomised comparison of narrow-band TL-01 phototherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32.
36. Pieternel CM, Pasker-de-Jong M, Wielink G, et al. Treatment with UV-B for psoriasis and nonmelanoma skin cancer. A systematic review of the literature. Arch Dermatol 1999; 135:834-40.
37. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005;44:355-60.
38. Cottin V, Tebib J, Souquet PJ, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996;109:933-8.
39. Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis. A cooperative clinical trial. J Invest Dermatol 1977; 68:328-35.
40. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994;73: 2759-64.
41. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A metaanalysis. Arch Dermatol 1998; 134:1582-5.
42. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999;141:497-501.
43. Stern RS, Fitzgerald E, Ellis CN, et al. The safety of etretinate as long-term therapy for psoriasis. Results of the etretinate follow-up study. J Am Acad Dermatol 1995; 33:44-52.
44. Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000;(3):CD000212.
45. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus ciclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
46. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996;21:399-408.
47. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155:1165-9.
48. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
49. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
50. Boffa MJ, Chalmers RJG, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995;133:774-8.
51. Zachariae H, Heickendorff L, Soegaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001;143:100-3.
52. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994;73: 2759-64.
53. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica 1983; 167:260-61.
54. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of ciclosporin in the treatment of psoriasis. Arch Dermatol 1996;132: 623-9.
55. Paul CE, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6.
56. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
57. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627-32.
58. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349: 2014-22.
59. Feldman SR, Boer Kimball A, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887-9.
60. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomised controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12.
61. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomised phase III trial. Br J Dermatol 2005;153:1192-9.
62. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.
63. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
64. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, doubleblind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.
65. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005;152:954-60.
66. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
67. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomised controlled trial. Br J Dermatol 2006;154:1161-8.
68. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-85.
69. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
70. Ellis CN, Mordin MM, Adler EY, et al. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomised, placebo-controlled phase II study. Am J Clin Dermatol 2003;4:131-9.
71. Krueger GG, Papp KA, Stough DB, et al. Randomized, doubleblind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
72. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004;150:317-26.
73. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
74. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003;206:307-15.
75. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912-21.
76. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
77. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80.
78. Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-33.
79. Menter A, Gordon K, Carey W, et al. Efficacy and safety during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.
80. Dubertret L, Sterry W, Bos JD, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-81.
81. Ortonne JP, Shear N, Shumack S, Henninger E; CLEAR Multinational Study Group. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005;5:13.
82. Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb randomised controlled trial. Int J Dermatol 2006;45:605-14.
83. Stern RS, Gange RW, Parrish JA, et al. Contribution of topical tar oil to ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol 1986;14:742-7.
84. Owen CM, Chalmers RJG, O'Sullivan T, Griffiths CEM. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2000;2:CD001976.
85. Chalmers RJG, O'Sullivan T, Owen CM, Griffiths CEM. Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000; 2:CD001213.
86. Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992;26:458-61.
87. Grimminger F, Mayser P, Papavassilis C, et al. A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. Clin Investig 1993; 71:634-43.
88. Marsland AM, Chalmers RJG, Hollis S, Leonardi-Bee J, Griffiths CEM. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006;1:CD001433.
89. Erkko P, Granlund H, Remitz A, et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998;139:997-1004.